Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
J Comp Eff Res
; 10(6): 457-467, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33626934
Lay abstract Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are used with fulvestrant to treat hormone receptor-positive, HER2-negative advanced breast cancer. This study aims to use data from clinical trials to compare how long patients live after starting treatment with PAL versus RIB and ABM. Since patients who enroll in different trials may have different characteristics, it is important to adjust for these differences for a more accurate comparison. Adjusting for these differences showed that patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with PAL lived for a similar length of time compared with those treated with RIB or ABM.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article